Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 11c

Bellerophon Reports First Quarter 2016 Financial Results and Provides Business Update

May 10, 2016 6:33 AM EDT

WARREN, N.J., May 10, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today reported financial results for the first quarter ended March 31, 2016 and provided a business update.

During the first quarter, we advanced our clinical and operational plans, stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. With receipt of FDA and EMA approval for our global Phase 3 clinical program for INOpulse for the treatment of Pulmonary Arterial Hypertension, or PAH, we look forward to commencing the enrollment of patients in the first of two Phase 3... More